CovX
This article was originally published in Start Up
Executive Summary
It's rare to find a drug development start-up that has grown to more than 50 people and raised over $100 million before putting its first molecule into the clinic. That's the history of CovX, which uses a humanized antibody as a scaffold for developing multiple drugs with the desirable properties of both the antibody and specific peptides or small molecules that are linked to it.